These obstacles are there to control costs , not to improve patient outcomes
[,,] PROBLEM STATEMENT OF THE STUDY Obesity poses the rising epidemic that substantially erodes health and quality of life, leading to a wide range of NCDs, including IR, dyslipidaemia, type 2 diabetes mellitus (T2DM), hypertension, obstructive sleep apnoea, steatohepatitis, gastro-oesophageal reflux, polycystic ovary syndrome and infertility cardiovascular syndrome, and specific types of carcinomas, together with other recurrent health issues, for example, shortness of breath, arthralgia and joint discomfort, across the globe
Treatment starts at 2.5 mg weekly solely for dose initiation, followed by incremental increases every 4 weeks by 2.5 mg until the effective maintenance dose is reached
In an asymmetrical mole, the two sides wont match in size or shape
None had received glucose-lowering therapy within six months prior to enrollment [24]
A 12 mg weekly dose consumes a 30 mg vial in two and a half weeks, which is inside a typical refrigerated beyond-use date for compounded peptides